Promising Clinical Developments and Strong Financial Position Support Buy Rating for Tenaya Therapeutics
Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report), retaining the price target ...
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...
MM&M11h
Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more
Viking Therapeutics reported updated, early-stage study results on its oral obesity drug candidate. Vertex Pharmaceuticals said the first patient with sickle cell disease was treated with Casgevy, its ...
Business Insider15h
Stifel Nicolaus Keeps Their Buy Rating on Trevi Therapeutics (TRVI)
The company’s shares opened today at $3.15. Samimy covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Viking Therapeutics, and Apellis Pharmaceuticals. According to ...